{"id":79352,"date":"2026-06-08T08:15:21","date_gmt":"2026-06-08T08:15:21","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/79352\/"},"modified":"2026-06-08T08:15:21","modified_gmt":"2026-06-08T08:15:21","slug":"roche-enters-2-billion-cancer-drug-agreement-with-nurix-therapeutics","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/79352\/","title":{"rendered":"Roche enters $2 billion cancer drug agreement with Nurix Therapeutics"},"content":{"rendered":"<p><a data-ylk=\"elm:icon;slk:Reuters;\" href=\"https:\/\/www.reuters.com\/\" target=\"_blank\" rel=\"nofollow noopener\"><img alt=\"Reuters\" loading=\"lazy\" width=\"171\" height=\"40\" decoding=\"async\" data-nimg=\"1\" class=\"pr-2.5 max-w-[150px] max-h-[40px] min-[601px]:max-w-[115px]\" style=\"color:transparent;max-width:auto;max-height:100%\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/https:\/\/s.yimg.com\/os\/creatr-uploaded-images\/2020-11\/62e21440-2fbd-11eb-95ff-5673fa3d2f9f.jpeg\"\/><\/a>Mon, June 8, 2026 at 7:50 AM UTC<img alt=\"\" fetchpriority=\"high\" width=\"976\" height=\"566\" decoding=\"async\" data-nimg=\"1\" class=\"standard-img w-full w-full h-auto\" style=\"color:transparent\" src=\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/06\/https:\/\/media.zenfs.com\/en\/reuters.com\/a9b21a40ce69a39aac650415e6ed0aa4.jpeg\"\/><\/p>\n<p>FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS\/Arnd Wiegmann\/File Photo<\/p>\n<p>ZURICH, June 8 (Reuters) &#8211; Swiss pharmaceutical giant Roche has entered an exclusive licensing \u200cand collaboration agreement with Nurix Therapeutics \u200cof up to $2.3 billion, the company said on Monday.<\/p>\n<p>\u2022 \u200bThe deal focuses on blood cancer drug bexobrutideg, which degrades targeted proteins and is planned to enter a phase III clinical trial \u200cinitiation for chronic \u2060lymphocytic leukaemia (CLL) in the summer<\/p>\n<p>\u2022 Nurix will receive $700 million upfront, with \u2060possible payouts for development, regulatory and sales milestones<\/p>\n<p>\u2022 &#8220;We believe bexobrutideg could represent a major \u200bleap forward \u200bin the fight \u200bagainst complex blood cancers \u200cand other diseases,&#8221; Levi Garraway, Roche chief medical officer and head of global product development said<\/p>\n<p>\u2022 The deal is expected to close in the third quarter of 2026<\/p>\n<p>\u2022 \u200cDevelopment costs for the drug \u200bwill be covered 60% \u200bby Roche \u200band 40% by Nurix<\/p>\n<p>\u2022 The companies \u200cwill co-commercialise the drug \u200bin the \u200bUnited States, where they will split the profits and losses equally, while Roche will \u200bcommercialise outside \u200cof the U.S., paying Nurix royalties<\/p>\n<p>(Reporting \u200bby Marleen Kaesebier and Oliver Hirt, \u200bEditing by Friederike Heine)<\/p>\n","protected":false},"excerpt":{"rendered":"Mon, June 8, 2026 at 7:50 AM UTC FILE PHOTO: The logo of Swiss drugmaker Roche is seen&hellip;\n","protected":false},"author":2,"featured_media":79353,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[471,19413,134],"class_list":["post-79352","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-blood-cancer","tag-collaboration-agreement","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116713496624693204","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/79352","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=79352"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/79352\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/79353"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=79352"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=79352"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=79352"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}